Results 61 to 70 of about 175,293 (159)

Predicting Maternal and Fetal Exposures of Elexacaftor–Tezacaftor–Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models

Clinical Pharmacology &Therapeutics, EarlyView.
The use of elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with increased fertility in women with cystic fibrosis (CF) and is increasingly used during pregnancy to support both maternal and fetal health. However, little is known about the pharmacokinetics (PK) of ETI during pregnancy, which is crucial for optimizing its efficacy and safety ...
Eunjin Hong, Mary F. Hebert, Emily Fay, Grant Turner, Patricia Eshaghian, Aaron Trimble, Peter S. Chung, Adupa P. Rao, Paul M. Beringer   +8 more
wiley   +1 more source

Antimicrobial utilization pattern in indoor patients of obstetrics and gynecology ward of a tertiary care hospital [PDF]

Background: Rational prescribing of antimicrobials is fundamentally necessary to reduce incidence of antimicrobial resistance. To evaluate the rationality of antimicrobial prescribing practices in patients admitted to obstetrics and gynecology ward of a ...
Chincholkar, Aparna, Korde, Vaishali, Sawant, Ankita   +2 more
core   +2 more sources

Factor Structure, Internal Consistency, and Measurement Invariance of the Eating Pathology Symptoms Inventory (EPSI) in Transgender and Gender‐Diverse Adults

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective This study aimed to examine the psychometric properties, including factor structure, internal consistency, and measurement invariance of the Eating Pathology Symptoms Inventory (EPSI) in a large national sample of transgender and gender‐diverse (TGD) adults. Method The sample consisted of 2098 TGD adults—including transgender men (n =
Jason M. Nagata, Christopher D. Otmar, Audrey Lopez, Emilio J. Compte, Jason M. Lavender, Tiffany A. Brown, Kelsie T. Forbush, Annesa Flentje, Micah E. Lubensky, Juno Obedin‐Maliver, Mitchell R. Lunn   +10 more
wiley   +1 more source

Introduction [PDF]

, 1980
The Department of Obstetrics and Gynecology welcomed the opportunity to present the 51st Annual McGuire Lecture Series. The lectures were designed to provide the primary care physician with information which is clinically useful and applicable to the ...
Hurt, W. Glenn
core   +1 more source

Direct Economic Burden of Post‐Cancer Treatment Pain Among Cancer Survivors in the United States: A Population‐Based Retrospective Longitudinal Study

The International Journal of Health Planning and Management, EarlyView.
ABSTRACT Purpose Post‐cancer treatment pain (PCTP) is prevalent among cancer survivors but remains understudied. It is critical to quantify PCTP prevalence over time and to estimate the resulting short and long‐term incremental healthcare expenditures (total, third‐party, and out‐of‐pocket) and out‐of‐pocket burden among cancer survivors.
Yves Paul Vincent Mbous, Rowida Mohamed, Uche Osahor, Traci J. LeMasters   +3 more
wiley   +1 more source

Research status of fetal hydrocephalus from 2003 to 2022 based on bibliometric analysis

Ibrain, EarlyView.
In this study, we extracted 613 articles related to hydrocephalus from the Web of Science Core Collection (WOSCC) database published from January 01, 2003 to December 31, 2022, and 613 articles were obtained after weight reduction using CiteSpace. CiteSpace and VOSviewer software were used to extract and visualize the elements of the article, including
Qian Li, Zheyu Song, Chenyang Zhai, Sajid Hussain, Wenxue Zhao, Shunwu Xiao   +5 more
wiley   +1 more source

Should the age range of the Dutch hrHPV‐based cervical cancer screening program be broadened? A modelling study using cohort effects

International Journal of Cancer, EarlyView.
What's New? Cervical cancer incidence in the Netherlands is increasing among women in younger birth cohorts. This raises concerns about the start and end ages of the country's human papillomavirus (HPV) screening program, which currently includes women ages 30 to 60.
Sylvia Kaljouw, Erik E. L. Jansen, Veerle J. C. Schevenhoven, Inge M. C. M. de Kok   +3 more
wiley   +1 more source

Obstetrics and Gynecology [PDF]

, 2007
中村 隆文, 塩崎 有宏, 斎藤 滋, 日高 隆雄, 柳楽 清文, 結城 浩良, 若杉 聡美   +6 more
core   +2 more sources

Nationwide implementation and evaluation of the Tumor‐First workflow for genetic testing in ovarian carcinoma

International Journal of Cancer, EarlyView.
What's New? The Tumor‐First workflow is a genetic testing strategy developed to detect pathogenic variants in ovarian cancer risk genes. Recently implemented in the Netherlands, this workflow aims to stratify germline testing while providing information on the effectiveness of PARP inhibitor therapy.
Vera M. Witjes, Joanne A. de Hullu, Dorien M. A. Hermkens, Yvonne H. C. M. Smolders, Julie E. M. Swillens, Sarah‐Lotte Slob, Tjalling Bosse, Marian J. E. Mourits, Margreet G. E. M. Ausems, Tumor‐First Implementation Group, Marjolijn J. L. Ligtenberg, Nicoline Hoogerbrugge, Saskia A.G.M. Cillessen, Johan J.P. Gille, Fenne L. Komdeur, Constantijne H. Mom, Malou L.H. Snijders, J. Margriet Collée, Hendrikus J. Dubbink, Floris H. Groenendijk, Esther Korpershoek, Eva Maria Roes, Christi J. van Asperen, Katja N. Gaarenstroom, Rob B. van der Luijt, Nienke van der Stoep, Elisabeth M.P. Steeghs, Marinus J. Blok, Loes F.S. Kooreman, Edward M. Leter, Brigitte F.M. Slangen, Ernst Jan M. Speel, Hester van Boven, Willemien J. van Driel, Frans B.L. Hogervorst, Lizet E. van der Kolk, Efraim H. Rosenberg, Joost Bart, Lieke P.V. Berger, Arja ter Elst, Annemarie H. van der Hout, Refika Yigit, Anne M.L. Jansen, Wouter Koole, Johanna Krol‐Veraar, Wendy W.J. de Leng, Ronald P. Zweemer, Marjolijn J.L. Ligtenberg, Arjen R. Mensenkamp, Janneke H.M. Schuurs‐Hoeijmakers, Michiel Simons   +50 more
wiley   +1 more source

The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer

International Journal of Cancer, EarlyView.
What's New? Women who are at high risk of breast cancer (BC), either because of a BRCA1/2 mutation or family history, require more aggressive screening. Here, the authors report on the clinical characteristics of the high‐risk women who developed BC during the TESTBREAST study. Of the 1108 participants, 124 (16.5%) developed breast cancer. Their median
Layla Andour, Sophie C. Hagenaars, Kiki Vangangelt, Janneke Aalberts, Valerie Rebattu, Dorien M. A. Berends van der Meer, Elma Meershoek‐Klein Kranenbarg, Katja N. Gaarenstroom, Christi J. van Asperen, Rob A. E. M. Tollenaar, Wilma E. Mesker, on behalf of the TESTBREAST study team, J. Aalberts, T. M. A. Berends‐van der Meer, S. C. Hagenaars, L. Andour, W.E. Mesker, R. A. E. M Tollenaar, W. M. Meershoek‐Klein Kranenbarg, K. N. Gaarenstroom, C. M. R. Haekens, K. B. M. I. Keymeulen, J. Remmelzwaal, M. Piek‐den Hartog, E. J. T. Rutgers, C. Drukker, C. Lemstra, A. Prozee, J. de Vries, A. Stam, C. Bandel, I. Meijer, A. E. Dassen, S. Makineli, E. E. van Oers‐Hazelzet, A. J. Witkamp, K. E. Schenk, W. van der Eijk, M. B. E. Menke‐Pluijmers, J. de Droog‐Laane, B. A. Kortmann   +40 more
wiley   +1 more source